AST-OPC1 / Lineage Cell Therap - LARVOL DELTA

LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1 (clinicaltrials.gov) - P=N/A | N=25 | Active, not recruiting | Sponsor: Lineage Cell Therapeutics, Inc.

New trial • CNS Disorders • Musculoskeletal Diseases • Orthopedics

LTFU Study of Subjects Who Received GRNOPC1 (clinicaltrials.gov) - P=N/A | N=5 | Active, not recruiting | Sponsor: Lineage Cell Therapeutics, Inc.

New trial • CNS Disorders • Musculoskeletal Diseases • Orthopedics

A phase 1/2a dose-escalation study of oligodendrocyte progenitor cells in individuals with subacute cervical spinal cord injury. (PubMed, J Neurosurg Spine) - P1/2 | "LCTOPC1 can be safely administered to participants in the subacute period after cervical SCI. The injection procedure, low-dose temporary immunosuppression regimen, and LCTOPC1 were well tolerated. The safety and neurological function data support further investigation to determine the efficacy of LCTOPC1 in the treatment of SCI. Clinical trial registration no.: NCT02302157 (ClinicalTrials.gov)."

Journal • P1/2 data • CNS Disorders • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Solid Tumor

Ten-year safety of pluripotent stem cell transplantation in acute thoracic spinal cord injury. (PubMed, J Neurosurg Spine) - P1/2 | "This study provides crucial first-in-human safety data supporting the pursuit of future human embryonic stem cell-derived therapies. While we cannot exclude the possibility of future adverse events, the experience in this trial provides evidence that this cell type can be well tolerated by patients, with an event-free period of up to 10 years. Based on the safety profile of LCTOPC1 obtained in this study, a cervical dose escalation trial was initiated (NCT02302157)."

Journal • Bone Marrow Transplantation • CNS Disorders • Orthopedics • Solid Tumor • Transplantation

Safety of direct injection of oligodendrocyte progenitor cells into the spinal cord of uninjured Göttingen minipigs. (PubMed, J Neurosurg Spine) - "These data strongly support the safety of intraparenchymal injection of LCTOPC1 into the spinal cord using a model anatomically similar to that of the human spinal cord. Furthermore, this research provides guidance for future clinical interventions, including mechanisms for precise positioning and anticipated volumes of biological payloads that can be safely delivered directly into uninjured portions of the spinal cord."

Clinical • Journal • CNS Disorders • Complement-mediated Rare Disorders • Immunology • Inflammation • Oncology • Orthopedics • Solid Tumor

Dose Escalation Study of AST-OPC1 in Spinal Cord Injury (clinicaltrials.gov) - P1/2; N=25; Completed; Sponsor: Asterias Biotherapeutics, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion